Background.Allergic rhinitis (AR) is a highly heterogeneous disease, and allergen-specific immunotherapy (AIT) is an effective treatment.This study aims to evaluate the circulating mas-related G protein-coupled receptor-X2 (MRGPRX2) and matrix metalloproteinase-12 Horse Vitamins (MMP-12) levels in evaluating disease severity and predicting efficacy of SLIT in AR patients.Methods.We enrolled 110 moderate-severe persist AR patients (AR group) and 40 healthy controls (HC group).
Circulating levels of MRGPRX2 and MMP-12 were measured, and their associations with disease severity were evaluated.All AR patients were assigned to receive sublingual immunotherapy (SLIT), and the efficacy was evaluated, and serum samples were collected at 1 year and 3 years after treatment.The correlations between serum MRGPRX2 and MMP-12 and clinical efficacy were assessed.Results.The serum concentrations of MRGPRX2 and MMP-12 were significantly higher in the AR group than the HC group, and the elevated MMP-12 levels were correlated with VAS and TNSS, and serum MRGPRX2 levels were correlated with VAS.
Finally, 100 and 80 patients completed 1-year and 3-year follow-up and were classified into effective and ineffective groups.Serum MRGPRX2 and MMP-12 levels were lower in the effective group than the ineffective group.Although serum MRGPRX2 and MMP-12 levels did not significantly change after 1 year SLIT, serum MMP-12 levels were decreased 3 years post-SLIT than baseline and 1 year post-SLIT levels.Receiver operating characteristic (ROC) showed that serum MMP-12 was a potential biomarker for Seat Shaft predicting the efficacy of SLIT.Conclusion.
Serum MRGPRX2 and MMP-12 appeared to be promising biological indicators in reflecting disease severity in AR patients.Moreover, circulating MMP-12 might serve as a reliable predictor for clinical responsiveness of SLIT.